Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy
Open Access
- 19 July 2008
- journal article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 6 (10) , 1697-1706
- https://doi.org/10.1111/j.1538-7836.2008.03089.x
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Idraparinux versus Standard Therapy for Venous Thromboembolic DiseaseNew England Journal of Medicine, 2007
- Latest medical treatment strategies for venous thromboembolismExpert Opinion on Pharmacotherapy, 2007
- Assessing, preventing, and treating venous thromboembolism: Evidence-based approachesAmerican Journal of Health-System Pharmacy, 2007
- Treatment of venous thromboembolismJournal of Thrombosis and Haemostasis, 2005
- Short- and long-acting synthetic pentasaccharides as antithrombotic agentsExpert Opinion on Investigational Drugs, 2005
- Synthetic heparin derivatives as new anticoagulant drugsDrug Discovery Today, 2005
- Fondaparinux: a Factor Xa inhibitor for antithrombotic therapyExpert Opinion on Pharmacotherapy, 2004
- A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluationJournal of Thrombosis and Haemostasis, 2004
- Synthesis of thrombin-inhibiting heparin mimetics without side effectsNature, 1999
- Synthetic Analogues of the Antithrombin III– Binding Pentasaccharide Sequence of HeparinArteriosclerosis, Thrombosis, and Vascular Biology, 1995